On March 8, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, reported that its Board of Directors has authorized a share repurchase program under which Fulgent may repurchase up to $250 million in shares of its common stock (Press release, Fulgent Pharma, MAR 8, 2022, View Source [SID1234609697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Given the volatility we have seen in our share price, we believe current trading levels present an attractive opportunity to implement a share repurchase program as a way to return capital to our shareholders," said Paul Kim, Chief Financial Officer of Fulgent. "With our current cash, cash equivalents and investments in marketable securities position now exceeding $1.0 billion, we believe we remain extremely well capitalized to make strategic investments to drive growth as we implement this share repurchase program."

The timing and amount of any shares repurchased will be determined by Fulgent’s management based on its evaluation of market conditions and other factors. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The repurchase program may be suspended or discontinued at any time. Any repurchased shares will be available for use in connection with its stock plans and for other corporate purposes.

The repurchase program will be funded using Fulgent’s working capital. Fulgent had approximately 30.3 million shares of common stock outstanding as of March 7, 2022.

On March 8, 2022 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics" or the "company") , a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, reported that members of its management team are scheduled to virtually participate in Oppenheimer’s 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 (Press release, Fulgent Pharma, MAR 8, 2022, View Source [SID1234609696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These representatives of the company will conduct a presentation beginning at approximately 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.

On March 8, 2022 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, reported that the company will host a conference call and live audio webcast on Tuesday, March 15, 2022, at 8:00 a.m. ET to review its fourth quarter and full year 2021 financial results and provide an update on the company (Press release, Gamida Cell, MAR 8, 2022, View Source [SID1234609695]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available on the "Investors & Media" section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 1696742. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

On March 8, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported that its Chief Executive Officer, Zachary Hornby, will present at the Oppenheimer 32nd Annual Healthcare Conference, which will take place virtually (Press release, Boundless Bio, MAR 8, 2022, View Source [SID1234609694]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, March 15, 2022
Time: 2:00 PM – 2:30 PM ET

On March 8, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext under the existing local coverage determination (LCD) (MolDX: Next-Generation Sequencing for Solid Tumors) (Press release, Guardant Health, MAR 8, 2022, View Source [SID1234609693]). Guardant360 TissueNext is the company’s first tissue-based test to help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The policy covers Guardant360 TissueNext for Medicare fee-for-service patients with advanced solid tumor cancers as a standalone service. "We are pleased that Medicare has taken this important step to make complete genomic profiling more widely available for patients with advanced cancers," said Helmy Eltoukhy, Guardant Health co-CEO.

Medicare’s policy decision adds to the coverage of Guardant Health tests for patients with advanced stage cancer. In December 2019, Palmetto GBA expanded LCD of the Guardant360 assay, making it the first liquid biopsy to be broadly covered for use across the vast majority of advanced solid tumor cancers.